An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
Diana Voorhees, M.A., CLS, MT, SH, CLCP, CPCO
Posts by the Author
One of the biggest danger areas that labs and their billing staffs face in COVID-19 test reimbursement is improper use of HCPCS code G2023.
What labs and billing managers need to know about multianalyte assays with algorithmic analyses coding for tests based on molecular platforms.
An overview and general briefing on some of the most common ICD codes concerns for labs.
Due to the common misuse of this modifier, the Centers for Medicare & Medicaid Services recently issued important new guidance on its proper use.
New CMS guidance includes information on how labs can avoid Medicare claims denials and documentation violations related to standing orders.
As of August 31, 2022, labs and other providers must use the new ABN labeled with the appropriate federal OMB Number (0938-0566) and CMS-R-131 to ensure they can bill Medicare beneficiaries for any lab tests or other services that Medicare doesn’t cover.
Use of these codes has frequently raised concerns for compliance due to a lack of clarity regarding when they’re appropriate.
While this reimbursement rule has been in effect since 2018, it can still be quite confusing; this article provides a guide to the basics.
A briefing of the current requirements you can use to avoid billing and coding errors at your own lab or pathology practice.